Molecular Profile Detail

Profile Name MET del exon14
Gene Variant Detail

MET del exon14 (gain of function)

Relevant Treatment Approaches MET Antibody MET Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET del exon14 lung squamous cell carcinoma sensitive MET Inhibitor Capmatinib Clinical Study Actionable In a clinical case study, Capmatinib (INC280) treatment resulted in a decreased tumor volume of 61% in a patient with lung squamous cell carcinoma harboring a deletion of MET exon 14 (PMID: 25971938). 25971938
MET del exon14 lung adenocarcinoma sensitive MET Inhibitor Crizotinib Clinical Study Actionable In a clinical case study, three patients with lung adenocarcinoma harboring a deletion of MET exon 14 demonstrated partial responses when treated with Xalkori (crizotinib) (PMID: 25971939). 25971939
MET del exon14 lung adenocarcinoma sensitive MET Inhibitor Glesatinib Clinical Study Actionable In a clinical study, a patient with lung adenocarcinoma harboring a deletion of MET exon 14 demonstrated a 66% reduction in target lesion size and maintained a partial response for 7 months when treated with Glesatinib (MGCD265) (PMID: 28765324). 28765324
MET del exon14 Advanced Solid Tumor sensitive MET Inhibitor Capmatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing MET deletion exon 14 were sensitive to Capmatinib (INC280) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). 28765324
MET del exon14 lung cancer decreased response MET Antibody MET Inhibitor Emibetuzumab Preclinical - Pdx Actionable In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping mutations (PMID: 28679766). 28679766
MET del exon14 Advanced Solid Tumor sensitive MET Inhibitor Glesatinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing deletion of MET exon 14 were sensitive to Glesatinib (MGCD265) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). 28765324
MET del exon14 lung adenocarcinoma sensitive MET Inhibitor Cabozantinib Clinical Study Actionable In a clinical study, a patient with lung adenocarcinoma harboring a deletion of MET exon 14 demonstrated a complete response via PERCIST criteria when treated with Cometriq (Cabometyx, cabozantinib) (PMID: 25971939). 25971939
MET del exon14 stomach cancer sensitive MET Inhibitor Glesatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in gastric cancer cells harboring MET exon 14 deletion and amplification of the mutant allele in culture, and resulted in tumor regression in cell line xenograft models (PMID: 28765324). 28765324
MET del exon14 lung cancer sensitive MET Inhibitor Glesatinib Preclinical - Cell culture Actionable In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth in lung cancer cells harboring MET exon 14 deletion and loss of the wild-type MET allele in culture (PMID: 28765324). 28765324
MET del exon14 Advanced Solid Tumor sensitive MET Inhibitor Crizotinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing MET del exon14 were sensitive to Xalkori (crizotinib) treatment in culture, demonstrating inhibition of spheroid growth (PMID: 28765324). 28765324
MET del exon14 non-small cell lung carcinoma sensitive MET Antibody Onartuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, Onartuzumab inhibited tumor growth and decreased MET expression in a non-small cell lung cancer xenograft model harboring MET exon 14 deletion (PMID: 23882082). 23882082
MET del exon14 stomach cancer sensitive MET Antibody SYM015 Preclinical - Cell line xenograft Actionable In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in cell line xenograft models of gastric cancer harboring MET exon 14 skipping (PMID: 28679766). 28679766
MET del exon14 lung cancer sensitive MET Antibody SYM015 Preclinical - Pdx Actionable In a preclinical study, SYM015 treatment resulted in sustained tumor growth inhibition in patient-derived xenograft (PDX) models of lung cancer harboring MET exon 14 skipping (PMID: 28679766). 28679766
MET del exon14 non-small cell lung carcinoma sensitive MET Antibody MET Inhibitor KTN0073-IgG1 Preclinical - Cell culture Actionable In a preclinical study, KTN0073-IgG1 inhibited growth of a non-small cell lung cancer cell line harboring deletion of MET exon 14 in culture (PMID: 27550450). 27550450
MET del exon14 stomach cancer decreased response MET Antibody MET Inhibitor Emibetuzumab Preclinical - Cell line xenograft Actionable In a preclinical study, Emibetuzumab (LY2875358) treatment resulted in initial tumor growth inhibition followed by regrowth in cell line xenograft models of gastric cancer harboring MET exon 14 skipping mutations (PMID: 28679766). 28679766
MET del exon14 Advanced Solid Tumor sensitive MET Antibody SYM015 Preclinical - Pdx & cell culture Actionable In a preclinical study, Sym015 inhibited growth of cancer cell lines harboring MET exon 14 deletion in culture, and inhibited tumor growth in patient-derived xenograft (PDX) models with MET exon 14 deletion (Cancer Res July 15 2016 (76) (14 Supplement) 1219). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02465060 Phase II Dabrafenib Trametinib Crizotinib Sunitinib Sapanisertib Nivolumab AZD4547 Dasatinib Binimetinib Adavosertib Osimertinib Trastuzumab Palbociclib Afatinib Capivasertib Defactinib GSK2636771 Vismodegib trastuzumab emtansine Larotrectinib Pertuzumab Taselisib Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting
NCT03260491 Phase I U3-1402 U3-1402 in Metastatic or Unresectable EGFR-mutant Non-Small Cell Lung Cancer Recruiting